Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by LUIS E FAYAD and L JEFFREY MEDEIROS.
LUIS E FAYAD
Connection Strength
1.728
L JEFFREY MEDEIROS
  1. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.117
  2. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012 Jan; 25(1):145-56.
    View in: PubMed
    Score: 0.101
  3. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012 Mar 15; 118(6):1566-73.
    View in: PubMed
    Score: 0.100
  4. Mantle cell lymphoma with a rare involvement of the testicle. Leuk Lymphoma. 2007 Jun; 48(6):1242-3.
    View in: PubMed
    Score: 0.074
  5. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol. 2024 Jul 02.
    View in: PubMed
    Score: 0.061
  6. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.
    View in: PubMed
    Score: 0.051
  7. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
    View in: PubMed
    Score: 0.048
  8. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629.
    View in: PubMed
    Score: 0.045
  9. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019 05 14; 3(9):1356-1367.
    View in: PubMed
    Score: 0.043
  10. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):244-250.
    View in: PubMed
    Score: 0.042
  11. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61.
    View in: PubMed
    Score: 0.041
  12. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 11; 183(4):578-587.
    View in: PubMed
    Score: 0.041
  13. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646.
    View in: PubMed
    Score: 0.040
  14. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
    View in: PubMed
    Score: 0.040
  15. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma. 2018 12; 59(12):2896-2903.
    View in: PubMed
    Score: 0.040
  16. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461.
    View in: PubMed
    Score: 0.039
  17. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311.
    View in: PubMed
    Score: 0.039
  18. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723.
    View in: PubMed
    Score: 0.038
  19. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.
    View in: PubMed
    Score: 0.037
  20. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
    View in: PubMed
    Score: 0.037
  21. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
    View in: PubMed
    Score: 0.036
  22. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
    View in: PubMed
    Score: 0.035
  23. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.
    View in: PubMed
    Score: 0.034
  24. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
    View in: PubMed
    Score: 0.034
  25. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
    View in: PubMed
    Score: 0.033
  26. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.032
  27. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma. 2016 Feb; 57(2):445-447.
    View in: PubMed
    Score: 0.032
  28. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):122-9.
    View in: PubMed
    Score: 0.032
  29. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015 May; 21(5):855-9.
    View in: PubMed
    Score: 0.032
  30. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
    View in: PubMed
    Score: 0.030
  31. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91.
    View in: PubMed
    Score: 0.030
  32. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2013 Aug; 37(8):1290-7.
    View in: PubMed
    Score: 0.029
  33. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(?) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8.
    View in: PubMed
    Score: 0.028
  34. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.
    View in: PubMed
    Score: 0.028
  35. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012 Jul; 36(7):1000-8.
    View in: PubMed
    Score: 0.026
  36. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma. 2012 May; 53(5):990-2.
    View in: PubMed
    Score: 0.026
  37. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66.
    View in: PubMed
    Score: 0.024
  38. Marginal zone lymphomas: factors that affect the final outcome. Cancer. 2010 Sep 15; 116(18):4291-8.
    View in: PubMed
    Score: 0.023
  39. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010 Sep 20; 28(27):4170-6.
    View in: PubMed
    Score: 0.023
  40. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol. 2009 Oct; 22(10):1312-20.
    View in: PubMed
    Score: 0.022
  41. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.020
  42. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007 Jan 01; 109(1):77-83.
    View in: PubMed
    Score: 0.018
  43. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
    View in: PubMed
    Score: 0.016
  44. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 01; 97(3):586-91.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.